双环[2.2.1]庚烷-1-胺 | 21245-51-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 双环[2.2.1]庚烷-1-胺
• 英文名称: 1-norbornylamine
• 英文别名: exo-Aminonorbornane；1-aminobicyclo<2.2.1>heptane；1-aminonorbornane；exo-norbornylamine；norbornyl amine；Bicyclo[2.2.1]heptan-1-amine
• CAS: 21245-51-2
• 化学式: C₇H₁₃N
• mdl: MFCD18826792
• 分子量: 111.187
• InChiKey: VUFQYRAKSQTZEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921300090

反应信息

• 作为反应物：
  描述：

  双环[2.2.1]庚烷-1-胺 在 磺酰氯 作用下， 以 Petroleum ether 为溶剂， 以72%的产率得到N,N'-bis(1-norbornyl)sulfamide
  参考文献：
  名称：

  cis-Diazenes. Viscosity effects, one-bond scission, and cis-trans isomerization

  摘要：

  DOI：

  10.1021/jo00296a026
• 作为产物：
  描述：

  exo,endo-2-bromobicyclo<2.2.1>heptane-1-carboxylic acid 在 sodium azide 、 硫酸 、 三正丁基氢锡 作用下， 以 氯仿 为溶剂， 生成 双环[2.2.1]庚烷-1-胺
  参考文献：
  名称：

  cis-Diazenes. Viscosity effects, one-bond scission, and cis-trans isomerization

  摘要：

  DOI：

  10.1021/jo00296a026

文献信息

• Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic
  申请人：——

  公开号：US20030187045A1

  公开（公告）日：2003-10-02

  The invention relates to novel compounds of the type of the imidazolidines of the formula I 1 in which R1 to R7 are as defined herein. In one embodiment, these compounds are used for the treatment of the central nervous system, of lipid metabolism, of infection by ectoparasites, of disorders of gall function and for improving the respiratory drive such as for treating respiratory distress. In another embodiment, the compounds increase the muscle tone of the upper respiratory tract, thus suppressing snoring.

  这项发明涉及公式I中咪唑啉类新化合物，其中R1至R7如本文所定义。在一个实施例中，这些化合物用于治疗中枢神经系统、脂质代谢、外寄生虫感染、胆囊功能紊乱以及改善呼吸驱动，例如用于治疗呼吸窘迫。在另一个实施例中，这些化合物增加上呼吸道的肌肉张力，从而抑制打鼾。
• SUBSTITUTED 4-PHENYLTETRAHYRDOISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS THEREOF, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USE
  申请人：LANG Hans-Jochen

  公开号：US20070225323A1

  公开（公告）日：2007-09-27

  The present invention relates to substituted 4-phenyltetrahydroisoquinoline compounds of the structure of formula I and pharmaceutical compositions comprising them wherein the R groups are herein defined. These are excellent inhibitors of the sodium-hydrogen exchanger (NHE), in particular of the sodium-hydrogen exchanger of subtype 3 (NHE3). As such these compounds are useful in the treatment of various disorders of the renal and respiratory systems such as acute or chronic renal failure, pulmonary complications, biliary function disorders, respiratory disorders such as snoring or sleep apneas and cardiovascular/central nervous system disorders such as stroke. More specifically, the present invention relates to substituted 4-phenyl-tetrahydroisoquinolines, derivatives thereof and compositions containing them formulated in combination with other compounds which also regulate the intracellular pH environment such as inhibitors of carbonic anhydrase and inhibitors of the transport systems that carry bicarbonate ions, such as of the sodium-bicarbonate co-transporter (NBC) or the sodium-dependent chloride-bicarbonate exchanger

  本发明涉及结构为式I的取代4-苯基四氢异喹啉化合物及包含它们的药物组合物，其中R基在此处定义。这些化合物是优秀的钠-氢交换体（NHE）抑制剂，特别是NHE3亚型的钠-氢交换体。因此，这些化合物在治疗肾脏和呼吸系统的各种疾病方面非常有用，如急性或慢性肾衰竭、肺部并发症、胆功能障碍、呼吸系统疾病如打鼾或睡眠呼吸暂停以及心血管/中枢神经系统疾病如中风。更具体地，本发明涉及取代的4-苯基四氢异喹啉、其衍生物以及含有它们的组合物，该组合物与其他调节细胞内pH环境的化合物一起配制，如碳酸酐酶抑制剂和携带碳酸氢根离子的转运系统的抑制剂，如钠-碳酸氢根共转运体（NBC）或钠依赖性氯化物-碳酸氢根交换体。
• Heterocyclic Compounds
  申请人：Yen Chi-Feng

  公开号：US20090264339A1

  公开（公告）日：2009-10-22

  This invention relates to heterocyclic compounds of the formulas shown in the specification. It also relates to methods for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, and tissue injuries with one of the heterocyclic compounds.

  这项发明涉及规范中所示的异环化合物。它还涉及使用其中一种异环化合物治疗炎症性疾病或免疫性疾病、发育性或退行性疾病以及组织损伤的方法。
• CARBOXYLIC ACID COMPOUND
  申请人：TODA Narihiro

  公开号：US20110053974A1

  公开（公告）日：2011-03-03

  To find a therapeutic agent and/or a preventive agent for diabetes mellitus or the like having excellent activity and safety. A compound represented by the following general formula (I), or a pharmacologically acceptable salt thereof. In the formula, X represents ═C(R5)- or ═N—; Y represents —O— or —NH—; L represents a bond or a substitutable C1-C3 alkylene group; M represents a substitutable C3-C10 cycloalkyl group, a substitutable C6-C10 aryl group, or a substitutable heterocyclic group; R 1 represents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 aliphatic acyl group, a C1-C6 alkoxy C1-C6 alkyl group, or a C6-C10 aryl group; and R 2 , R 3 , R 4 , and R 5 may be the same or different and each represent a hydrogen atom, a halogen atom, a C1-C3 alkyl group, a C1-C3 haloalkyl group, a C1-C3 alkoxy group, or a nitro group. In this connection, the alkyl group moieties of R 1 and R 2 may be bonded to each other to form a 5- to 6-membered heterocyclic ring containing one oxygen atom.

  寻找具有优异活性和安全性的治疗剂和/或预防剂，用于糖尿病或类似疾病。以下通用式（I）所代表的化合物，或其药理学上可接受的盐。在该式中，X代表 ═C(R5)- 或 ═N—；Y代表 —O— 或 —NH—；L代表键或可替代的C1-C3烷基链；M代表可替代的C3-C10环烷基，可替代的C6-C10芳基，或可替代的杂环基；R1代表C1-C6烷基，C3-C10环烷基，C1-C6卤代烷基，C2-C6烯基，C2-C6炔基，C1-C6脂肪酰基，C1-C6烷氧基C1-C6烷基，或C6-C10芳基；而R2、R3、R4和R5可以相同也可以不同，每个代表氢原子，卤原子，C1-C3烷基，C1-C3卤代烷基，C1-C3烷氧基，或硝基。在这种情况下，R1和R2的烷基基团可以结合在一起形成含有一个氧原子的5-至6-成员杂环环。
• [EN] DIHYDROOROTATE DEHYDROGENASE INHIBITORS<br/>[FR] INHIBITEURS DE DIHYDROOROTATE DÉSHYDROGÉNASE
  申请人：JANSSEN BIOTECH INC

  公开号：WO2020212897A1

  公开（公告）日：2020-10-22

  Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, X, and Y are defined herein.

  揭示了一种通过调节DHODH来治疗受影响的疾病、紊乱或医疗状况的化合物、组合物和方法。这些化合物由以下式（I）所代表：其中R1、R2、R3、R4、X和Y在此处定义。